| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $24K | +0.0% | — |
| SG&A Expense | $190K | -28.3% | -26.9% |
| Operating Income | -$554K | -22.2% | -222.4% |
| Net Income | -$554K | -22.2% | -22.4% |
| EPS (Basic) | $0.00 | — | — |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $50K | -45.2% | +1541.8% |
| Current Assets | $61K | -46.1% | +121.2% |
| Total Assets | $173K | -25.3% | -1.1% |
| Current Liabilities | $3.0M | +17.2% | +28.4% |
| Total Liabilities | $3.0M | +17.2% | +28.4% |
| Stockholders' Equity | -$2.8M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$959K | — | — |
| Financing Cash Flow | $928K | — | — |
| -30.9% |